1. Home
  2. ATNI vs ALLO Comparison

ATNI vs ALLO Comparison

Compare ATNI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATN International Inc.

ATNI

ATN International Inc.

HOLD

Current Price

$20.98

Market Cap

226.4M

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.42

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNI
ALLO
Founded
1987
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
226.4M
252.9M
IPO Year
1991
2018

Fundamental Metrics

Financial Performance
Metric
ATNI
ALLO
Price
$20.98
$1.42
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$8.67
AVG Volume (30 Days)
55.8K
2.3M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
5.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$724,308,000.00
N/A
Revenue This Year
$1.77
N/A
Revenue Next Year
$2.06
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.76
$0.86
52 Week High
$23.60
$3.78

Technical Indicators

Market Signals
Indicator
ATNI
ALLO
Relative Strength Index (RSI) 64.97 57.36
Support Level $21.05 $1.39
Resistance Level $21.99 $1.52
Average True Range (ATR) 0.79 0.10
MACD -0.09 0.01
Stochastic Oscillator 59.41 68.75

Price Performance

Historical Comparison
ATNI
ALLO

About ATNI ATN International Inc.

ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: